nodes	percent_of_prediction	percent_of_DWPC	metapath
Metixene—HTR2C—Serotonin receptors—HTR2A—conduct disorder	0.0326	0.0371	CbGpPWpGaD
Metixene—CHRM4—Monoamine GPCRs—DRD4—conduct disorder	0.0285	0.0325	CbGpPWpGaD
Metixene—CHRM5—Monoamine GPCRs—DRD4—conduct disorder	0.0273	0.0311	CbGpPWpGaD
Metixene—CHRM4—Amine ligand-binding receptors—DRD4—conduct disorder	0.024	0.0273	CbGpPWpGaD
Metixene—CHRM5—Amine ligand-binding receptors—DRD4—conduct disorder	0.023	0.0261	CbGpPWpGaD
Metixene—HTR2C—Monoamine GPCRs—DRD4—conduct disorder	0.0223	0.0253	CbGpPWpGaD
Metixene—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—conduct disorder	0.0217	0.0247	CbGpPWpGaD
Metixene—CHRM1—Monoamine GPCRs—DRD4—conduct disorder	0.0192	0.0219	CbGpPWpGaD
Metixene—CHRM3—Monoamine GPCRs—DRD4—conduct disorder	0.0192	0.0218	CbGpPWpGaD
Metixene—CHRM2—Monoamine GPCRs—DRD4—conduct disorder	0.019	0.0216	CbGpPWpGaD
Metixene—HTR2C—Amine ligand-binding receptors—DRD4—conduct disorder	0.0187	0.0213	CbGpPWpGaD
Metixene—CHRM4—Monoamine GPCRs—HTR2A—conduct disorder	0.0186	0.0212	CbGpPWpGaD
Metixene—CHRM5—Monoamine GPCRs—HTR2A—conduct disorder	0.0178	0.0203	CbGpPWpGaD
Metixene—Protriptyline—SLC6A4—conduct disorder	0.0169	0.14	CrCbGaD
Metixene—Mirtazapine—DRD4—conduct disorder	0.0164	0.136	CrCbGaD
Metixene—CHRM1—Amine ligand-binding receptors—DRD4—conduct disorder	0.0162	0.0184	CbGpPWpGaD
Metixene—CHRM3—Amine ligand-binding receptors—DRD4—conduct disorder	0.0161	0.0183	CbGpPWpGaD
Metixene—CHRM2—Amine ligand-binding receptors—DRD4—conduct disorder	0.016	0.0182	CbGpPWpGaD
Metixene—CHRM4—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0156	0.0178	CbGpPWpGaD
Metixene—CHRM5—Amine ligand-binding receptors—HTR2A—conduct disorder	0.015	0.017	CbGpPWpGaD
Metixene—HTR2C—Monoamine GPCRs—HTR2A—conduct disorder	0.0145	0.0165	CbGpPWpGaD
Metixene—CHRM1—Monoamine GPCRs—HTR2A—conduct disorder	0.0125	0.0143	CbGpPWpGaD
Metixene—CHRM3—Monoamine GPCRs—HTR2A—conduct disorder	0.0125	0.0142	CbGpPWpGaD
Metixene—CHRM2—Monoamine GPCRs—HTR2A—conduct disorder	0.0124	0.0141	CbGpPWpGaD
Metixene—CHRM4—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0122	0.0139	CbGpPWpGaD
Metixene—HTR2C—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0122	0.0139	CbGpPWpGaD
Metixene—CHRM5—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0117	0.0133	CbGpPWpGaD
Metixene—CHRM1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0105	0.012	CbGpPWpGaD
Metixene—CHRM3—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0105	0.012	CbGpPWpGaD
Metixene—CHRM2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0104	0.0118	CbGpPWpGaD
Metixene—Mirtazapine—SLC6A4—conduct disorder	0.00985	0.0814	CrCbGaD
Metixene—Quetiapine—DRD4—conduct disorder	0.00936	0.0773	CrCbGaD
Metixene—Promazine—DRD4—conduct disorder	0.0086	0.0711	CrCbGaD
Metixene—CHRM3—GPCRs, Other—DRD4—conduct disorder	0.00852	0.00969	CbGpPWpGaD
Metixene—CHRM2—GPCRs, Other—DRD4—conduct disorder	0.00843	0.0096	CbGpPWpGaD
Metixene—CHRM4—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00842	0.00958	CbGpPWpGaD
Metixene—Maprotiline—HTR2A—conduct disorder	0.00828	0.0684	CrCbGaD
Metixene—CHRM1—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.00824	0.00938	CbGpPWpGaD
Metixene—CHRM3—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.00822	0.00935	CbGpPWpGaD
Metixene—CHRM2—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.00814	0.00926	CbGpPWpGaD
Metixene—CHRM5—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00807	0.00918	CbGpPWpGaD
Metixene—Mirtazapine—HTR2A—conduct disorder	0.00757	0.0626	CrCbGaD
Metixene—Cyproheptadine—HTR2A—conduct disorder	0.00734	0.0607	CrCbGaD
Metixene—Mianserin—SLC6A4—conduct disorder	0.00724	0.0598	CrCbGaD
Metixene—HTR2C—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00657	0.00748	CbGpPWpGaD
Metixene—CHRM4—GPCR ligand binding—CGA—conduct disorder	0.00641	0.0073	CbGpPWpGaD
Metixene—Mesoridazine—HTR2A—conduct disorder	0.00636	0.0525	CrCbGaD
Metixene—CHRM5—GPCR ligand binding—CGA—conduct disorder	0.00614	0.00699	CbGpPWpGaD
Metixene—CHRM4—G alpha (i) signalling events—DRD4—conduct disorder	0.00593	0.00675	CbGpPWpGaD
Metixene—CHRM2—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.00583	0.00663	CbGpPWpGaD
Metixene—CHRM1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00568	0.00646	CbGpPWpGaD
Metixene—CHRM3—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00566	0.00644	CbGpPWpGaD
Metixene—CHRM2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00561	0.00638	CbGpPWpGaD
Metixene—Mianserin—HTR2A—conduct disorder	0.00557	0.046	CrCbGaD
Metixene—CHRM3—GPCRs, Other—HTR2A—conduct disorder	0.00556	0.00632	CbGpPWpGaD
Metixene—CHRM4—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0055	0.00626	CbGpPWpGaD
Metixene—CHRM2—GPCRs, Other—HTR2A—conduct disorder	0.0055	0.00626	CbGpPWpGaD
Metixene—CHRM5—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00527	0.006	CbGpPWpGaD
Metixene—HTR2C—GPCR ligand binding—CGA—conduct disorder	0.00501	0.0057	CbGpPWpGaD
Metixene—CHRM1—Circadian rythm related genes—SLC6A4—conduct disorder	0.00482	0.00548	CbGpPWpGaD
Metixene—Thioridazine—HTR2A—conduct disorder	0.00479	0.0396	CrCbGaD
Metixene—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00472	0.00537	CbGpPWpGaD
Metixene—CHRM1—Circadian rythm related genes—DRD4—conduct disorder	0.00453	0.00516	CbGpPWpGaD
Metixene—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00452	0.00514	CbGpPWpGaD
Metixene—Promethazine—HTR2A—conduct disorder	0.00451	0.0373	CrCbGaD
Metixene—CHRM5—G alpha (q) signalling events—HTR2A—conduct disorder	0.00445	0.00506	CbGpPWpGaD
Metixene—CHRM2—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00439	0.00499	CbGpPWpGaD
Metixene—CHRM1—GPCR ligand binding—CGA—conduct disorder	0.00432	0.00492	CbGpPWpGaD
Metixene—Quetiapine—HTR2A—conduct disorder	0.00432	0.0357	CrCbGaD
Metixene—CHRM3—GPCR ligand binding—CGA—conduct disorder	0.00431	0.0049	CbGpPWpGaD
Metixene—HTR2C—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0043	0.00489	CbGpPWpGaD
Metixene—CHRM2—GPCR ligand binding—CGA—conduct disorder	0.00427	0.00486	CbGpPWpGaD
Metixene—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00398	0.00453	CbGpPWpGaD
Metixene—Promazine—HTR2A—conduct disorder	0.00397	0.0328	CrCbGaD
Metixene—CHRM2—G alpha (i) signalling events—DRD4—conduct disorder	0.00395	0.00449	CbGpPWpGaD
Metixene—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00371	0.00422	CbGpPWpGaD
Metixene—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0037	0.00421	CbGpPWpGaD
Metixene—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00368	0.00419	CbGpPWpGaD
Metixene—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00366	0.00417	CbGpPWpGaD
Metixene—HTR2C—G alpha (q) signalling events—HTR2A—conduct disorder	0.00363	0.00413	CbGpPWpGaD
Metixene—CHRM4—GPCR downstream signaling—CGA—conduct disorder	0.00362	0.00412	CbGpPWpGaD
Metixene—CHRM4—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00359	0.00409	CbGpPWpGaD
Metixene—CHRM4—GPCR ligand binding—DRD4—conduct disorder	0.00359	0.00409	CbGpPWpGaD
Metixene—CHRM2—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00358	0.00407	CbGpPWpGaD
Metixene—CHRM5—GPCR downstream signaling—CGA—conduct disorder	0.00347	0.00395	CbGpPWpGaD
Metixene—CHRM5—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00344	0.00391	CbGpPWpGaD
Metixene—CHRM5—GPCR ligand binding—DRD4—conduct disorder	0.00344	0.00391	CbGpPWpGaD
Metixene—CHRM4—Signaling by GPCR—CGA—conduct disorder	0.00329	0.00374	CbGpPWpGaD
Metixene—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00324	0.00369	CbGpPWpGaD
Metixene—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00318	0.00362	CbGpPWpGaD
Metixene—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00317	0.00361	CbGpPWpGaD
Metixene—CHRM5—Signaling by GPCR—CGA—conduct disorder	0.00315	0.00359	CbGpPWpGaD
Metixene—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00314	0.00357	CbGpPWpGaD
Metixene—CHRM1—G alpha (q) signalling events—HTR2A—conduct disorder	0.00313	0.00356	CbGpPWpGaD
Metixene—CHRM3—G alpha (q) signalling events—HTR2A—conduct disorder	0.00312	0.00355	CbGpPWpGaD
Metixene—CHRM4—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00308	0.0035	CbGpPWpGaD
Metixene—CHRM5—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00295	0.00335	CbGpPWpGaD
Metixene—HTR2C—GPCR downstream signaling—CGA—conduct disorder	0.00283	0.00322	CbGpPWpGaD
Metixene—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.0028	0.00319	CbGpPWpGaD
Metixene—HTR2C—GPCR ligand binding—DRD4—conduct disorder	0.0028	0.00319	CbGpPWpGaD
Metixene—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.0028	0.00319	CbGpPWpGaD
Metixene—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00279	0.00318	CbGpPWpGaD
Metixene—HTR2C—Signaling by GPCR—CGA—conduct disorder	0.00257	0.00292	CbGpPWpGaD
Metixene—CHRM1—GPCR downstream signaling—CGA—conduct disorder	0.00244	0.00278	CbGpPWpGaD
Metixene—CHRM3—GPCR downstream signaling—CGA—conduct disorder	0.00244	0.00277	CbGpPWpGaD
Metixene—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00242	0.00276	CbGpPWpGaD
Metixene—CHRM1—GPCR ligand binding—DRD4—conduct disorder	0.00242	0.00276	CbGpPWpGaD
Metixene—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00241	0.00275	CbGpPWpGaD
Metixene—CHRM3—GPCR ligand binding—DRD4—conduct disorder	0.00241	0.00275	CbGpPWpGaD
Metixene—CHRM2—GPCR downstream signaling—CGA—conduct disorder	0.00241	0.00274	CbGpPWpGaD
Metixene—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.0024	0.00273	CbGpPWpGaD
Metixene—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00239	0.00272	CbGpPWpGaD
Metixene—CHRM2—GPCR ligand binding—DRD4—conduct disorder	0.00239	0.00272	CbGpPWpGaD
Metixene—CHRM4—GPCR ligand binding—HTR2A—conduct disorder	0.00234	0.00267	CbGpPWpGaD
Metixene—CHRM5—GPCR ligand binding—HTR2A—conduct disorder	0.00224	0.00255	CbGpPWpGaD
Metixene—CHRM1—Signaling by GPCR—CGA—conduct disorder	0.00222	0.00252	CbGpPWpGaD
Metixene—CHRM3—Signaling by GPCR—CGA—conduct disorder	0.00221	0.00252	CbGpPWpGaD
Metixene—CHRM2—Signaling by GPCR—CGA—conduct disorder	0.00219	0.00249	CbGpPWpGaD
Metixene—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00207	0.00236	CbGpPWpGaD
Metixene—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00207	0.00235	CbGpPWpGaD
Metixene—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00205	0.00233	CbGpPWpGaD
Metixene—CHRM4—GPCR downstream signaling—DRD4—conduct disorder	0.00203	0.00231	CbGpPWpGaD
Metixene—CHRM4—Signaling Pathways—CGA—conduct disorder	0.00194	0.00221	CbGpPWpGaD
Metixene—CHRM5—GPCR downstream signaling—DRD4—conduct disorder	0.00194	0.00221	CbGpPWpGaD
Metixene—CHRM2—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00189	0.00216	CbGpPWpGaD
Metixene—CHRM5—Signaling Pathways—CGA—conduct disorder	0.00186	0.00212	CbGpPWpGaD
Metixene—CHRM4—Signaling by GPCR—DRD4—conduct disorder	0.00184	0.0021	CbGpPWpGaD
Metixene—HTR2C—GPCR ligand binding—HTR2A—conduct disorder	0.00183	0.00208	CbGpPWpGaD
Metixene—CHRM5—Signaling by GPCR—DRD4—conduct disorder	0.00177	0.00201	CbGpPWpGaD
Metixene—HTR2C—GPCR downstream signaling—DRD4—conduct disorder	0.00158	0.0018	CbGpPWpGaD
Metixene—CHRM1—GPCR ligand binding—HTR2A—conduct disorder	0.00158	0.0018	CbGpPWpGaD
Metixene—CHRM3—GPCR ligand binding—HTR2A—conduct disorder	0.00158	0.00179	CbGpPWpGaD
Metixene—CHRM1—Circadian rythm related genes—EP300—conduct disorder	0.00157	0.00178	CbGpPWpGaD
Metixene—CHRM3—Metabolism—CGA—conduct disorder	0.00156	0.00178	CbGpPWpGaD
Metixene—CHRM2—GPCR ligand binding—HTR2A—conduct disorder	0.00156	0.00177	CbGpPWpGaD
Metixene—CHRM4—Signaling Pathways—WASF1—conduct disorder	0.00156	0.00177	CbGpPWpGaD
Metixene—HTR2C—Signaling Pathways—CGA—conduct disorder	0.00152	0.00173	CbGpPWpGaD
Metixene—CHRM5—Signaling Pathways—WASF1—conduct disorder	0.00149	0.0017	CbGpPWpGaD
Metixene—HTR2C—Signaling by GPCR—DRD4—conduct disorder	0.00144	0.00164	CbGpPWpGaD
Metixene—CHRM1—GPCR downstream signaling—DRD4—conduct disorder	0.00137	0.00156	CbGpPWpGaD
Metixene—CHRM3—GPCR downstream signaling—DRD4—conduct disorder	0.00136	0.00155	CbGpPWpGaD
Metixene—CHRM2—GPCR downstream signaling—DRD4—conduct disorder	0.00135	0.00154	CbGpPWpGaD
Metixene—CHRM4—GPCR downstream signaling—HTR2A—conduct disorder	0.00132	0.00151	CbGpPWpGaD
Metixene—CHRM1—Signaling Pathways—CGA—conduct disorder	0.00131	0.00149	CbGpPWpGaD
Metixene—CHRM3—Signaling Pathways—CGA—conduct disorder	0.00131	0.00149	CbGpPWpGaD
Metixene—CHRM2—Signaling Pathways—CGA—conduct disorder	0.00129	0.00147	CbGpPWpGaD
Metixene—CHRM5—GPCR downstream signaling—HTR2A—conduct disorder	0.00127	0.00144	CbGpPWpGaD
Metixene—CHRM1—Signaling by GPCR—DRD4—conduct disorder	0.00124	0.00141	CbGpPWpGaD
Metixene—CHRM3—Signaling by GPCR—DRD4—conduct disorder	0.00124	0.00141	CbGpPWpGaD
Metixene—CHRM2—Signaling by GPCR—DRD4—conduct disorder	0.00123	0.0014	CbGpPWpGaD
Metixene—HTR2C—Signaling Pathways—WASF1—conduct disorder	0.00122	0.00138	CbGpPWpGaD
Metixene—CHRM4—Signaling by GPCR—HTR2A—conduct disorder	0.0012	0.00137	CbGpPWpGaD
Metixene—CHRM5—Signaling by GPCR—HTR2A—conduct disorder	0.00115	0.00131	CbGpPWpGaD
Metixene—CHRM4—Signaling Pathways—DRD4—conduct disorder	0.00109	0.00124	CbGpPWpGaD
Metixene—CHRM1—Signaling Pathways—WASF1—conduct disorder	0.00105	0.0012	CbGpPWpGaD
Metixene—CHRM3—Signaling Pathways—WASF1—conduct disorder	0.00105	0.00119	CbGpPWpGaD
Metixene—CHRM5—Signaling Pathways—DRD4—conduct disorder	0.00104	0.00119	CbGpPWpGaD
Metixene—CHRM2—Signaling Pathways—WASF1—conduct disorder	0.00104	0.00118	CbGpPWpGaD
Metixene—HTR2C—GPCR downstream signaling—HTR2A—conduct disorder	0.00103	0.00118	CbGpPWpGaD
Metixene—HTR2C—Signaling by GPCR—HTR2A—conduct disorder	0.000939	0.00107	CbGpPWpGaD
Metixene—CHRM1—GPCR downstream signaling—HTR2A—conduct disorder	0.000893	0.00102	CbGpPWpGaD
Metixene—CHRM3—GPCR downstream signaling—HTR2A—conduct disorder	0.00089	0.00101	CbGpPWpGaD
Metixene—CHRM2—GPCR downstream signaling—HTR2A—conduct disorder	0.000881	0.001	CbGpPWpGaD
Metixene—HTR2C—Signaling Pathways—DRD4—conduct disorder	0.00085	0.000967	CbGpPWpGaD
Metixene—CHRM1—Signaling by GPCR—HTR2A—conduct disorder	0.000811	0.000923	CbGpPWpGaD
Metixene—CHRM3—Signaling by GPCR—HTR2A—conduct disorder	0.000808	0.00092	CbGpPWpGaD
Metixene—CHRM2—Signaling by GPCR—HTR2A—conduct disorder	0.0008	0.000911	CbGpPWpGaD
Metixene—CHRM1—Signaling Pathways—DRD4—conduct disorder	0.000734	0.000835	CbGpPWpGaD
Metixene—CHRM3—Signaling Pathways—DRD4—conduct disorder	0.000732	0.000833	CbGpPWpGaD
Metixene—CHRM2—Signaling Pathways—DRD4—conduct disorder	0.000725	0.000825	CbGpPWpGaD
Metixene—CHRM4—Signaling Pathways—HTR2A—conduct disorder	0.00071	0.000808	CbGpPWpGaD
Metixene—CHRM3—Metabolism—COMT—conduct disorder	0.000705	0.000803	CbGpPWpGaD
Metixene—CHRM3—Metabolism—MAOA—conduct disorder	0.0007	0.000797	CbGpPWpGaD
Metixene—CHRM5—Signaling Pathways—HTR2A—conduct disorder	0.00068	0.000774	CbGpPWpGaD
Metixene—HTR2C—Signaling Pathways—HTR2A—conduct disorder	0.000555	0.000631	CbGpPWpGaD
Metixene—CHRM1—Signaling Pathways—HTR2A—conduct disorder	0.000479	0.000545	CbGpPWpGaD
Metixene—CHRM3—Signaling Pathways—HTR2A—conduct disorder	0.000477	0.000543	CbGpPWpGaD
Metixene—CHRM2—Signaling Pathways—HTR2A—conduct disorder	0.000473	0.000538	CbGpPWpGaD
Metixene—CHRM4—Signaling Pathways—EP300—conduct disorder	0.000376	0.000428	CbGpPWpGaD
Metixene—CHRM5—Signaling Pathways—EP300—conduct disorder	0.00036	0.00041	CbGpPWpGaD
Metixene—CHRM3—Metabolism—EP300—conduct disorder	0.000303	0.000344	CbGpPWpGaD
Metixene—HTR2C—Signaling Pathways—EP300—conduct disorder	0.000294	0.000334	CbGpPWpGaD
Metixene—CHRM1—Signaling Pathways—EP300—conduct disorder	0.000254	0.000289	CbGpPWpGaD
Metixene—CHRM3—Signaling Pathways—EP300—conduct disorder	0.000253	0.000288	CbGpPWpGaD
Metixene—CHRM2—Signaling Pathways—EP300—conduct disorder	0.000251	0.000285	CbGpPWpGaD
